Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 2/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 4/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13223236 | 0.88 | CDC25B (0.48) | CDC25BKMT2AMEN1POLBRAD52 | |
| SCHEMBL12387589 | 0.88 | SYK (0.48) | CDC25BKMT2AMEN1POLBRAD52 | |
| SCHEMBL17130325 | 0.85 | IDO1 (0.53) | CDC25BKMT2AMEN1POLBRAD52 | |
| SCHEMBL3809017 | 0.84 | SYK (0.55) | KMT2AMEN1POLBRAD52GFER | |
| SCHEMBL18385065 | 0.79 | KCNH3 (0.46) | TAAR1 | |
| SCHEMBL25830630 | 0.79 | KCNH3 (0.46) | TAAR1 | |
| SCHEMBL18391969 | 0.78 | KCNH3 (0.58) | KMT2AMEN1TAAR1 | |
| SCHEMBL17130323 | 0.76 | CDC25B (0.45) | CDC25BKMT2AMEN1POLBRAD52 | |
| SCHEMBL7564159 | 0.76 | SYK (0.64) | KMT2AMEN1POLBRAD52GFER | |
| SCHEMBL12513290 | 0.74 | CYP3A4 (0.74) | KMT2AMEN1POLBRAD52GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200199249-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | Akamara Therapeutics, Inc. (US) | 2020-06-25 | — | — | US | disclosed |
| US-10533059-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2020-01-14 | — | — | US | disclosed |
| US-20170014528-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2017-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014528-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | ABCG2, ADAM8, TIE1 | CDC25B 2257/4885CDK9 611/4885KMT2A 1836/4885 |
| US-20200199249-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | ABCG2, FCGR2A, ABCB1 | CDC25B 2120/4885CDK9 1545/4885KMT2A 1933/4885 |
| US-10533059-B2 | Targeted drug delivery through affinity based linkers | ABCG2, ADAM8, TIE1 | CDC25B 2257/4885CDK9 611/4885KMT2A 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.